Safety and Efficacy of Ultra-Early Tirofiban Treatment Post Intravenous Thrombolysis in Non-Cardioembolic Acute Ischemic Stroke Patients

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2500106176

Enrollment

Unknown

Registered

2025-07-18

Start date

2025-07-20

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute ischemic stroke

Interventions

Ultra-Early (initiating tirofiban within 2 hours post rt-PA):None

Early (initiating tirofiban within 2-24 hours post rt-PA):None

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.age>=18 years; 2.symptom onset to treatment within 4.5 hours, or 4.5 to 9 hours with CT/MRI infarction /hypoperfusion mismatch or DWI-FLAIR mismatch; 3.Pre-thrombolysis NIHSS score 4 to 25;

Exclusion criteria

Exclusion criteria: 1.resence of any of the cardiac sources of embolism, including chronic or paroxysmal atrial fibrillation, rheumatic valvulopathy, dilated cardiomyopathy, or mechanical valve; 2.bridging endovascular treatment; 3.pre-stroke modified Rankin Scale (mRS)>1; 4.interrupting IVT; 5.thrombolysis with urokinase-type Plasminogen Activator or tenecteplase; 6.missing critical data; 7.re-thrombolysis; 8.refusal of hospitalization;

Design outcomes

Primary

Measure	Time frame
symptomatic intracranial hemorrhage;change of NIHSS at 24 hours post rt-PA;90-day mRS scores;	—

Secondary

Measure	Time frame
intracranial hemorrhage;90-day mortality;	—

Countries

China

Contacts

Public ContactZhangMeng

Army Medical Center of PLA

zhangmeng861@qq.com+86 23 68757816

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026